Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cilta-cel (JNJ-68284528) in relapsed or refractory multiple myeloma (Japan, Phase 1b-2)
jRCT1080224949Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2019
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
01
Overview
Phase 2, open-label, single-arm trial of ciltacabtagene autoleucel in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Started Nov 2019; status: completed.
02
Drugs
ciltacabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT1080224949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080224949.